Truist Securities Reiterates Buy on Sutro Biopharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $25.
September 06, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sutro Biopharma's stock rating has been reiterated as 'Buy' by Truist Securities with a maintained price target of $25.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Sutro Biopharma. The maintained price target of $25 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100